Author:
EL Ezzi Asmahan A.,EL-Saidi Mohammed A.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Polito M, Minardi D, Recchioni A, Giannulis I, De Sio G, Muzzonigro G. Serum markers for monitoring of prostatic carcinoma. Prostate 1997; 33(3): 208–216.
2. Andriole GL, Pinsky PF, Levin DL, Gelmann EP, Crawford ED, Reding D, Prorok PC, Gohagan JK. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: biopsy rates and cancer characteristics of initial T0 screen (II), American Urological Association (AUA), San Francisco, CA, May 2004.
3. Bunting PS, DeBoer G, Choo R, Danjoux C, Klotz L, Fleshner N. Intraindividual variation of PSA, free PSA and complexed PSA in a cohort of patients with prostate cancer managed with watchful observation. Clin Biochem 2002; 35: 471–475.
4. Catalona WJ, Loeb S. The PSA era is not over for prostate cancer. Eur Urol 2005; 48(4): 541–545.
5. Albers P. Do we need the final results of the ERSPC trial? Eur Urol 2006; 51(2): 291–292.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献